Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LEONEL REYES JR.

Allopathic & Osteopathic Physicians Family Medicine

NPI
1841302049
CMS profile
220107
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,875.29

31 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,702.41 7
Food and Beverage $1,160.73 23
Education $12.15 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Biogen, Inc. $1,516.89 8
ModernaTX, Inc. $943.24 8
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $234.63 12
Alkermes, Inc. $122.48 1
Lilly USA, LLC $51.14 1
ABBVIE INC. $6.91 1

Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LEONEL REYES JR.

NPI 1841302049 · CMS profile ID 220107

Allopathic & Osteopathic Physicians / Family Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841302049?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LEONEL REYES JR., NPI 1841302049, CMS profile ID 220107. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841302049?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LEONEL REYES JR., NPI 1841302049, CMS profile ID 220107. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841302049?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LEONEL REYES JR., NPI 1841302049, CMS profile ID 220107, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1841302049?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

31 matching records · $2,875.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 31 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–31 of 31.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $22.4912/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143305885 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $22.0611/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143305881 CMS
Alkermes, Inc. $122.4810/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120580257 CMS
Lilly USA, LLC $51.1410/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135151654 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $28.4210/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143305877 CMS
ABBVIE INC. $6.9109/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105940036 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $20.7108/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143305869 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4.1508/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143305873 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $23.6108/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143305865 CMS
Biogen, Inc. $67.8707/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104871280 CMS
Biogen, Inc. $78.0507/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104814109 CMS
Biogen, Inc. $92.2907/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104820746 CMS
Biogen, Inc. $130.0007/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104874746 CMS
Biogen, Inc. $300.4607/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104805169 CMS
Biogen, Inc. $418.8607/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104822972 CMS
Biogen, Inc. $261.8007/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104828708 CMS
Biogen, Inc. $167.5607/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104876990 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $21.4907/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143305862 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $12.1506/03/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143305854 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $22.0206/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143305858 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $19.2105/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143305851 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $17.4403/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143305847 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $20.8802/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143305843 CMS
ModernaTX, Inc. $292.0901/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560834 CMS
ModernaTX, Inc. $191.3001/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560836 CMS
ModernaTX, Inc. $150.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560838 CMS
ModernaTX, Inc. $159.8501/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560840 CMS
ModernaTX, Inc. $50.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560842 CMS
ModernaTX, Inc. $25.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560844 CMS
ModernaTX, Inc. $50.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560846 CMS
ModernaTX, Inc. $25.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560848 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $382.31 5
PY2020 $516.96 25
PY2021 $254.93 16
PY2022 $565.96 18
PY2023 $1,847.77 31
PY2024 $2,875.29 31
PY2025 $3,306.12 27

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $755,211.02 111
PY2024 Recipient $1,229.18 7
PY2024 Principal investigator $859,657.92 144
PY2023 Recipient $884.12 7
PY2023 Principal investigator $2,118,069.52 144
PY2022 Recipient $3,289.97 13
PY2022 Principal investigator $555,785.63 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

151 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $250.92 12/31/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 998414741
Principal investigator 1 AstraZeneca Pharmaceuticals LP $758.22 12/31/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 991133539
Principal investigator 1 ModernaTX, Inc. $143,983.94 12/22/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1042339589
Principal investigator 1 PFIZER INC. $10,137.60 12/21/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045869499
Principal investigator 1 SANOFI US SERVICES INC. $3,119.95 12/20/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1035970647
Principal investigator 1 Chiesi USA, Inc. $712.80 12/14/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051620557
Principal investigator 1 Chiesi USA, Inc. $712.80 12/14/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051620563
Principal investigator 1 SANOFI PASTEUR INC. $2,000.00 12/14/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035899181
Principal investigator 1 ABBVIE INC. $2,750.00 12/13/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 998411619
Principal investigator 1 SANOFI PASTEUR INC. $560.00 12/13/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035899169
Principal investigator 1 SANOFI PASTEUR INC. $240.00 12/13/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035899193
Principal investigator 1 SANOFI PASTEUR INC. $560.00 12/13/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035899205
Principal investigator 1 SANOFI PASTEUR INC. $560.00 12/13/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035899217
Principal investigator 1 ABBVIE INC. $3,692.00 12/07/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 998411089
Principal investigator 1 Chiesi USA, Inc. $1,700.00 12/07/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051618817
Principal investigator 1 PFIZER INC. $2,701.70 12/07/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046400861
Principal investigator 1 PFIZER INC. $513.00 12/06/2023 Non-covered Recipient Entity
Sun Research Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046441559
Principal investigator 1 ABBVIE INC. $10,250.00 12/04/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 998409945
Principal investigator 1 PFIZER INC. $770.86 12/02/2023 Non-covered Recipient Entity
Sun Research Institute
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046364641
Principal investigator 1 PFIZER INC. $47,065.42 11/25/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046379133
Principal investigator 1 PFIZER INC. $1,587.60 11/09/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046381923
Principal investigator 1 ModernaTX, Inc. $841.00 11/08/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1042339611
Principal investigator 1 SANOFI US SERVICES INC. $12,373.22 11/08/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1035970637
Principal investigator 1 PFIZER INC. $8,632.65 11/03/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046387733
Principal investigator 1 Chiesi USA, Inc. $1,700.00 11/01/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051615675
Principal investigator 1 PFIZER INC. $385.43 10/31/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046424832
Principal investigator 1 PFIZER INC. $17,247.20 10/27/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045866401
Principal investigator 1 PFIZER INC. $10,145.78 10/27/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046395427
Principal investigator 1 SANOFI US SERVICES INC. $1,085.04 10/27/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1035970657
Principal investigator 1 Janssen Research & Development, LLC $1,376.00 10/25/2023 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 986130993
Principal investigator 1 PFIZER INC. $27,528.69 10/24/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046426899
Principal investigator 1 SANOFI US SERVICES INC. $3,002.08 10/18/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1035970627
Recipient AbbVie Inc. $50.00 10/13/2023 Covered Recipient Physician Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 998354449
Recipient AbbVie Inc. $65.00 10/13/2023 Covered Recipient Physician Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 998354451
Recipient AbbVie Inc. $25.00 10/13/2023 Covered Recipient Physician Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 998354453
Recipient AbbVie Inc. $16.36 10/13/2023 Covered Recipient Physician Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 998354455
Principal investigator 1 ModernaTX, Inc. $143.70 10/13/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1042339607
Principal investigator 1 ModernaTX, Inc. $63.75 10/13/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1042339609
Principal investigator 1 ABBVIE INC. $1,195.52 10/12/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998403933
Recipient AbbVie Inc. $125.01 10/12/2023 Covered Recipient Physician Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 998354443
Recipient AbbVie Inc. $353.09 10/12/2023 Covered Recipient Physician Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 998354445
Recipient AbbVie Inc. $249.66 10/12/2023 Covered Recipient Physician Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 998354447
Principal investigator 1 PFIZER INC. $22,610.42 10/12/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046348317
Principal investigator 1 Janssen Research & Development, LLC $1,700.00 10/11/2023 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 986130995
Principal investigator 1 SANOFI US SERVICES INC. $600.00 10/11/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1035970667
Principal investigator 1 ABBVIE INC. $10,750.00 10/04/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 998401795
Principal investigator 1 ModernaTX, Inc. $507.60 10/04/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042339579
Principal investigator 1 Bausch Health US, LLC $16,250.00 09/22/2023 Non-covered Recipient Entity
Sun Research Institute, LLC
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) No dispute reported 06/30/2026 1055196251
Principal investigator 1 Janssen Research & Development, LLC $8,338.00 09/22/2023 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 986130989
Principal investigator 1 SANOFI US SERVICES INC. $550.00 09/20/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1035970503
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 09/20/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1035970525
Principal investigator 1 SANOFI PASTEUR INC. $2,154.24 09/15/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035899107
Principal investigator 1 SANOFI PASTEUR INC. $2,692.80 09/15/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035899119
Principal investigator 1 SANOFI US SERVICES INC. $900.00 09/15/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1035970513
Principal investigator 1 SANOFI US SERVICES INC. $9,458.92 09/15/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1035970537
Principal investigator 1 PFIZER INC. $11,787.60 09/14/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046389959
Principal investigator 1 SANOFI PASTEUR INC. $1,346.40 09/14/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035899095
Principal investigator 1 ABBVIE INC. $291.60 09/13/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998399545
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/13/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042339563
Principal investigator 1 SANOFI PASTEUR INC. $3,096.72 09/11/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035899133
Principal investigator 1 Bausch Health US, LLC $21,955.25 09/06/2023 Non-covered Recipient Entity
Sun Research Institute, LLC
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) No dispute reported 06/30/2026 1055196245
Principal investigator 1 SANOFI PASTEUR INC. $500.00 09/05/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035899083
Principal investigator 1 Bausch Health US, LLC $16,976.25 08/25/2023 Non-covered Recipient Entity
Sun Research Institute, LLC
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) No dispute reported 06/30/2026 1055196249
Principal investigator 1 PFIZER INC. $48,470.33 08/24/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046431149
Principal investigator 1 Janssen Research & Development, LLC $2,229.00 08/16/2023 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 986130991
Principal investigator 1 ModernaTX, Inc. $188.84 08/16/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042339507
Principal investigator 1 VIVUS LLC $1,455.00 08/04/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600899
Principal investigator 1 PFIZER INC. $8,048.70 07/27/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046412031
Principal investigator 1 PFIZER INC. $15,301.59 07/25/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046410409
Principal investigator 1 GlaxoSmithKline, LLC. $797.00 07/24/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1006234333
Principal investigator 1 PFIZER INC. $1,857.60 07/21/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046495977
Principal investigator 1 PFIZER INC. $19,352.95 07/08/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046347941
Principal investigator 1 PFIZER INC. $2,620.86 07/08/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046487857
Principal investigator 1 PFIZER INC. $25,622.50 07/06/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045883897
Principal investigator 1 PFIZER INC. $9,736.55 06/27/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045883913
Principal investigator 1 PFIZER INC. $95,450.48 06/24/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046517571
Principal investigator 1 PFIZER INC. $1,857.60 06/22/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046508715
Principal investigator 1 PFIZER INC. $2,226.16 06/15/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046511627
Principal investigator 1 Janssen Research & Development, LLC $1,950.00 06/09/2023 Non-covered Recipient Entity
Sun Rsrch Inst
CNTO1959CRD3004 No dispute reported 06/30/2026 986131243
Principal investigator 1 Janssen Research & Development, LLC $2,210.00 06/09/2023 Non-covered Recipient Entity
Sun Rsrch Inst
CNTO1959CRD3004 No dispute reported 06/30/2026 986131245
Principal investigator 1 ABBVIE INC. $5,188.64 06/08/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998385833
Principal investigator 1 PFIZER INC. $2,606.85 06/08/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046500817
Principal investigator 1 PFIZER INC. $29,855.26 06/03/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046508333
Principal investigator 1 PFIZER INC. $22,348.58 05/27/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046522046
Principal investigator 1 VIVUS LLC $8,100.00 05/26/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600889
Principal investigator 1 VIVUS LLC $2,700.00 05/26/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600891
Principal investigator 1 VIVUS LLC $8,903.00 05/26/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600893
Principal investigator 1 VIVUS LLC $8,903.00 05/26/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600895
Principal investigator 1 VIVUS LLC $6,677.25 05/26/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600897
Principal investigator 1 PFIZER INC. $20,899.13 05/25/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046523623
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,611.07 05/24/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 991127775
Principal investigator 1 ABBVIE INC. $2,500.00 05/23/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate (SELECT-EARLY) No dispute reported 06/30/2026 998384241
Principal investigator 1 Janssen Research & Development, LLC $7,000.00 05/17/2023 Non-covered Recipient Entity
Sun Rsrch Inst
70033093AFL3002 No dispute reported 06/30/2026 986130987
Principal investigator 1 GlaxoSmithKline, LLC. $797.00 05/12/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1006234345
Principal investigator 1 PFIZER INC. $1,997.00 05/12/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046525471
Principal investigator 1 ABBVIE INC. $728.32 05/11/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998382855
Principal investigator 1 PFIZER INC. $9,684.74 05/06/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046521437
Principal investigator 1 Bausch Health US, LLC $1,700.00 05/04/2023 Non-covered Recipient Entity
Sun Research Institute, LLC
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) No dispute reported 06/30/2026 1055196247
Principal investigator 1 ModernaTX, Inc. $2,128.00 05/03/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042339489
Principal investigator 1 ModernaTX, Inc. $1,702.40 05/03/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042339491
Principal investigator 1 PFIZER INC. $108,528.81 04/25/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046474269
Principal investigator 1 GlaxoSmithKline, LLC. $797.00 04/24/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1006234325
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 04/19/2023 Non-covered Recipient Entity
Sun Rsrch Inst
CNTO1959CRD3004 No dispute reported 06/30/2026 986131247
Principal investigator 1 Janssen Research & Development, LLC $2,175.00 04/19/2023 Non-covered Recipient Entity
Sun Rsrch Inst
CNTO1959CRD3004 No dispute reported 06/30/2026 986131249
Principal investigator 1 PFIZER INC. $12,742.55 04/15/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046476239
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 04/14/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1006234339
Principal investigator 1 ABBVIE INC. $3,442.56 04/13/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998378559
Principal investigator 1 Chiesi USA, Inc. $5,500.00 04/12/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593249
Principal investigator 1 Chiesi USA, Inc. $1,500.00 04/12/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593251
Principal investigator 1 Chiesi USA, Inc. $550.00 04/12/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051593253
Principal investigator 1 PFIZER INC. $5,816.99 04/12/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046482329
Principal investigator 1 SANOFI PASTEUR INC. $374,448.75 04/10/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035898905
Principal investigator 1 Chiesi USA, Inc. $8,250.00 04/06/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) No dispute reported 06/30/2026 1051592919
Principal investigator 1 Chiesi USA, Inc. $375.00 04/05/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24?g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800?g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1051592875
Principal investigator 1 ModernaTX, Inc. $275.38 04/05/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042339487
Principal investigator 1 PFIZER INC. $10,921.50 04/05/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046475697
Principal investigator 1 VIVUS LLC $6,577.00 03/30/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600873
Principal investigator 1 VIVUS LLC $3,288.50 03/30/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600875
Principal investigator 1 VIVUS LLC $8,440.00 03/30/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600877
Principal investigator 1 VIVUS LLC $9,350.00 03/30/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600879
Principal investigator 1 VIVUS LLC $4,932.75 03/30/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600881
Principal investigator 1 VIVUS LLC $7,530.00 03/30/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600883
Principal investigator 1 VIVUS LLC $4,932.75 03/30/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600885
Principal investigator 1 VIVUS LLC $485.00 03/30/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600887
Principal investigator 1 SANOFI PASTEUR INC. $181,082.03 03/29/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035898893
Principal investigator 1 SANOFI PASTEUR INC. $6,500.00 03/29/2023 Non-covered Recipient Entity
Sun Research Inst Llc
A parallel-group, Phase II/III, age de-escalation, dose-escalation, modified double-blind, multi-armed, placebo-controlled study to assess the safety and the effectiveness (immunogenicity) of a SARS-CoV-2 Adjuvanted Recombinant Protein Vaccine for prevention against COVID-19 in healthy children No dispute reported 06/30/2026 1035898925
Principal investigator 1 PFIZER INC. $18,892.69 03/24/2023 Non-covered Recipient Entity
Sun Research Institute LLC
A PHASE 3 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY OF A 6VALENT OSPABASED LYME DISEASE VACCINE VLA15 IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE No dispute reported 06/30/2026 1046447603
Principal investigator 1 PFIZER INC. $26,909.55 03/24/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046485297
Principal investigator 1 ABBVIE INC. $2,683.52 03/16/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998374433
Principal investigator 1 PFIZER INC. $6,804.00 03/15/2023 Non-covered Recipient Entity
Sun Research Institute LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046461691
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,093.20 03/10/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 No dispute reported 06/30/2026 991136651
Principal investigator 1 ABBVIE INC. $605.30 02/21/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) No dispute reported 06/30/2026 998371569
Principal investigator 1 ABBVIE INC. $560.00 02/21/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) No dispute reported 06/30/2026 998371571
Principal investigator 1 ModernaTX, Inc. $43,994.66 02/17/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042339485
Principal investigator 1 GlaxoSmithKline, LLC. $4,428.00 02/10/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1006234351
Principal investigator 1 ABBVIE INC. $2,714.24 02/09/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998370113
Principal investigator 1 SANOFI PASTEUR INC. $9,500.00 02/09/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035898937
Principal investigator 1 SANOFI PASTEUR INC. $1,200.00 02/09/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035898949
Principal investigator 1 SANOFI PASTEUR INC. $750.00 02/09/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035898961
Principal investigator 1 SANOFI PASTEUR INC. $700.00 02/09/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035898973
Principal investigator 1 SANOFI PASTEUR INC. $150.00 02/09/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035898983
Principal investigator 1 ABBVIE INC. $640.00 02/06/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate (SELECT-EARLY) No dispute reported 06/30/2026 998368815
Principal investigator 1 Bausch Health US, LLC $12,820.50 02/03/2023 Non-covered Recipient Entity
Sun Research Institute, LLC
A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel-group Study of the Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C) No dispute reported 06/30/2026 1055196243
Principal investigator 1 ABBVIE INC. $2,500.00 01/31/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) No dispute reported 06/30/2026 998367865
Principal investigator 1 SANOFI PASTEUR INC. $338,570.08 01/31/2023 Non-covered Recipient Entity
Sun Research Inst Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035898913
Principal investigator 1 ABBVIE INC. $1,797.00 01/26/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998367413
Principal investigator 1 ABBVIE INC. $2,500.00 01/19/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) No dispute reported 06/30/2026 998367043
Principal investigator 1 VIVUS LLC $7,500.00 01/13/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE LLC
A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject No dispute reported 06/30/2026 973600871
Principal investigator 1 ABBVIE INC. $2,892.16 01/12/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 998366429
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,441.00 01/05/2023 Non-covered Recipient Entity
Sun Research Institute
Phase II Study SLE - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 1027454951
Principal investigator 1 ModernaTX, Inc. $763.98 01/04/2023 Non-covered Recipient Entity
SUN RESEARCH INSTITUTE
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1042339483